Transition Therapeutics Announces Fiscal 2007 Year End Financi...(- - Issued on exercise of ...),Health

Issued on exercise of

Exchange Rights 137,733 1,009,437 - -

Exchange Rights

expired unexercised - - 242,500 -

Expiry of share

purchase warrants - - 486,615 -

Issued on acquisition

of ENI, net 2,109,479 10,727,317 - -

Issued to acquire

patent portfolio 46,055 286,000 - -

Cancellation of shares

issued to ENI (98,328) (559,475) 559,475 -

Stock options exercised 2,545 13,054 - (5,038)

Stock options expired - - 369,431 (369,431)

Stock-based compensation

expense - - - 405,699

Net loss for the year - - - -

-------------------------------------------------------------------------

Balance, June 30,

2006 17,494,269 99,563,853 4,469,987 774,858

-------------------------------------------------------------------------

Adjustment to opening

retained earnings for

change in accounting

policy related to

research inventory - - - -

Stock options exercised 63,654 601,571 - (221,177)

Stock options expired - - 17,765 (17,765)

Stock-based

compensation expense - - - 1,002,480

Issued pursuant to

private placement,

net 2,986,867 23,964,751 - -

Issued on acquisition

of NeuroMedix Inc.,

net 685,951 9,858,143 - -

Net loss for the year
'/>"/>